Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TTNP > SEC Filings for TTNP > Form 8-K on 5-Jul-2013All Recent SEC Filings




Entry into a Material Definitive Agreement, Financial Statements and Ex

Item 1.01. Entry Into a Definitive Material Agreement.

Amendment to License Agreement

On July 2, 2013, Titan Pharmaceuticals, Inc. (the "Company") and Braeburn Pharmaceuticals Sprl ("Braeburn") entered into a second amendment (the "Amendment") to the License Agreement dated December 14, 2012, as amended (the "Agreement") primarily to establish and provide the parameters for a committee comprised of representatives of Titan and Braeburn responsible for and with the authority to make all decisions regarding the development and implementation of a strategic plan to seek approval from the U.S. Food and Drug Administration ("FDA") of ProbuphineŽ for subdermal use in the maintenance treatment of adult patients with opioid dependence, including development of the strategy for all written and oral communications with the FDA. The Amendment also makes Braeburn the primary contact for FDA communications regarding the Probuphine New Drug Application.

A copy of the Amendment is attached hereto as Exhibit 10.1 and the description thereof contained in this Current Report on Form 8-K is qualified in its entirety be reference to such exhibit.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  No.                                     Description

10.1         Amendment dated July 2, 2013 to License Agreement dated December 14,
             2012 between Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals

  Add TTNP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TTNP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.